文献速递临床试验与 GCP基础与转化研究

阿仑单抗诱导后低剂量依维莫司联合低剂量他克莫司:肺移植随机前瞻性试验

Combined low-dose everolimus and low-dose tacrolimus after Alemtuzumab induction therapy: a randomized prospective trial in lung transplantation.
PubMed 文献 · Trials · 2021-01-04

BACKGROUND: Long-term outcomes of lung transplantation are severely affected by comorbidities and development of chronic rejection.…

要点

  • 肺移植后阿仑单抗诱导,采用低剂量他克莫司联合低剂量依维莫司维持免疫抑制。
  • 主要终点为24个月内eGFR变化,评估肾功能保护效果。
  • 探索性评估调节性免疫细胞状态与移植物接受度。

核心结论

  • 阿仑单抗诱导后早期引入低剂量依维莫司联合低剂量他克莫司,可能通过进一步减少他克莫司用量改善肾功能,并可能对调节性免疫细胞产生允许性作用。

主要发现

  • 原文未报告试验结果;主要终点为分析新低剂量免疫抑制方案对肾功能的影响,以eGFR变化衡量。
  • 将用流式细胞术和基因表达分析评估患者的免疫调节状态。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Long-term outcomes of lung transplantation are severely affected by comorbidities and development of chronic rejection. Among the comorbidities, kidney insufficiency is one of the most frequent and it is mainly caused by the cumulative effect of calcineurin inhibitors (CNIs). Currently, the most used immunosuppression protocols worldwide include induction therapy and a triple-drug maintenance immunosuppression, with one calcineurin inhibitor, one anti-proliferative drug, and steroids. Our center has pioneered the use of alemtuzumab as induction therapy, showing promising results in terms of short- and long-term outcomes. The use of alemtuzumab followed by a low-dose double drug maintenance immunosuppression, in fact, led to better kidney function along with excellent results in terms of acute rejection, chronic lung allograft dysfunction, and survival (Benazzo et al., PLoS One 14(1):e0210443, 2019). The hypothesis driving the proposed clinical trial is that de novo introduction of low-dose everolimus early after transplantation could further improve kidney function via a further reduction of tacrolimus. Based on evidences from kidney transplantation, moreover, alemtuzumab induction therapy followed by a low-dose everolimus and low-dose tacrolimus may have a permissive action on regulatory immune cells thus stimulating allograft acceptance. METHODS: A randomized prospective clinical trial has been set up to answer the research hypothesis. One hundred ten patients will be randomized in two groups. Treatment group will receive the new maintenance immunosuppression protocol based on low-dose tacrolimus and low-dose everolimus and the control group will receive our standard immunosuppression protocol. Both groups will receive alemtuzumab induction therapy. The primary endpoint of the study is to analyze the effect of the new low-dose immunosuppression protocol on kidney function in terms of eGFR change. The study will have a duration of 24 months from the time of randomization. Immunomodulatory status of the patients will be assessed with flow cytometry and gene expression analysis. DISCUSSION: For the first time in the field of lung transplantation, this trial proposes the combined use of significantly reduced tacrolimus and everolimus after alemtuzumab induction. The new protocol may have a twofold advantage: (1) further reduction of nephrotoxic tacrolimus and (2) permissive influence on regulatory cells development with further reduction of rejection episodes. TRIAL REGISTRATION: EUDRACT Nr 2018-001680-24. Registered on 15 May 2018.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Benazzo A, Cho A, Nechay A, et al. Combined low-dose everolimus and low-dose tacrolimus after Alemtuzumab induction therapy: a randomized prospective trial in lung transplantation. Trials. 2021. PMID: 33397442. doi:10.1186/s13063-020-04843-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。